Niederer Kraft Frey is acting as counsel to Idorsia

Niederer Kraft Frey is acting as counsel to Idorsia in the rights offering that Idorsia launched on October 8th. The targeted gross proceeds from the offering of CHF 575 million will be used to support the regulatory filing and, if approved, commercial launch of daridorexant, Idorsia’s dual orexin receptor antagonist, and to fund the clinical development of its other late-stage compounds as well as early-stage pipeline assets.

The NKF team is led by partner Philipp Haas (pictured) working with senior associates Deirdre Ní Annracháin and Andrea Giger, associate Shu Bernet-Zhang, and junior associates Sven Pinter and Stephanie Huchler (all Capital Markets).

FabioAdmin

SHARE